%0 Journal Article
%A Langen, K. J.
%A Tonn, J. C.
%A Weller, M.
%A Galldiks, N.
%T Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]
%J Journal of neuro-oncology
%V 120
%N 3
%@ 0167-594x
%C Dordrecht [u.a.]
%I Springer Science + Business Media B.V
%M FZJ-2014-04588
%P 665-666
%D 2014
%X o the Editor,We have read with interest the review by Ryken et al. about the role of imaging in the management of progressive glioblastoma [1]. In general, we agree with this review but we cannot support the opinion that the routine use of Positron-Emission-Tomography (PET) to identify progression of glioblastoma is not recommendable.The authors have considered PET using the amino acid tracer 11C-methyl-l-methionine (MET), but the use of MET is limited to PET centers with an on-site cyclotron due the short half-life of 11C (20.4 min). In recent years, the clinical application of 18F-labeled amino acids such as O-(2-18F-fluoroethyl)-l-tyrosine (FET) or 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine (FDOPA) has spread considerably due to the logistical advantages of the 18F label (half-life, 109.8 min) [2]. FET can be produced with high yields similar to the widely used FDG and distributed in a satellite concept [3]. In Europe, MET PET has been replaced in many centers by the more convenie ...
%F PUB:(DE-HGF)16
%9 Journal Article
%U <Go to ISI:>//WOS:000345286700028
%R 10.1007/s11060-014-1594-z
%U https://juser.fz-juelich.de/record/155422